Nothing Special   »   [go: up one dir, main page]

DK1121137T3 - Fremgangsmåde til udryddelse af tumorer og tumorassocierede endotelceller under anvendelse af adenovirus af adenovirus-mutanter - Google Patents

Fremgangsmåde til udryddelse af tumorer og tumorassocierede endotelceller under anvendelse af adenovirus af adenovirus-mutanter

Info

Publication number
DK1121137T3
DK1121137T3 DK99953196T DK99953196T DK1121137T3 DK 1121137 T3 DK1121137 T3 DK 1121137T3 DK 99953196 T DK99953196 T DK 99953196T DK 99953196 T DK99953196 T DK 99953196T DK 1121137 T3 DK1121137 T3 DK 1121137T3
Authority
DK
Denmark
Prior art keywords
adenovirus
endothelial cells
mutants
eradication
tumors
Prior art date
Application number
DK99953196T
Other languages
Danish (da)
English (en)
Inventor
Angelica Williams
Carla Heise
Adam Sampson-Johannes
Meisa Propst
David Kirn
Original Assignee
Onyx Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onyx Pharma Inc filed Critical Onyx Pharma Inc
Application granted granted Critical
Publication of DK1121137T3 publication Critical patent/DK1121137T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK99953196T 1998-10-26 1999-10-15 Fremgangsmåde til udryddelse af tumorer og tumorassocierede endotelceller under anvendelse af adenovirus af adenovirus-mutanter DK1121137T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10570198P 1998-10-26 1998-10-26
US12130099P 1999-02-23 1999-02-23

Publications (1)

Publication Number Publication Date
DK1121137T3 true DK1121137T3 (da) 2005-11-14

Family

ID=26802854

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99953196T DK1121137T3 (da) 1998-10-26 1999-10-15 Fremgangsmåde til udryddelse af tumorer og tumorassocierede endotelceller under anvendelse af adenovirus af adenovirus-mutanter

Country Status (11)

Country Link
US (1) US20020037274A1 (zh)
EP (1) EP1121137B1 (zh)
JP (1) JP2004517798A (zh)
CN (1) CN1333689A (zh)
AT (1) ATE299708T1 (zh)
AU (1) AU775611B2 (zh)
CA (1) CA2348634A1 (zh)
DE (1) DE69926251T2 (zh)
DK (1) DK1121137T3 (zh)
ES (1) ES2245831T3 (zh)
WO (1) WO2000024408A1 (zh)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040175362A1 (en) * 1999-05-12 2004-09-09 Curiel David T. Infectivity-enhanced conditionally-replicative adenovirus and uses thereof
ATE413807T1 (de) * 2001-01-12 2008-11-15 Sbarro Health Res Organization Hemmung der pathologischen angiogenese in vivo
US7906311B2 (en) * 2002-03-20 2011-03-15 Merial Limited Cotton rat lung cells for virus culture
US20040191761A1 (en) * 2003-03-27 2004-09-30 Routes John M. Modified adenoviral E1A constructs and methods of use thereof
KR100746122B1 (ko) 2004-05-10 2007-08-03 연세대학교 산학협력단 Ｒｂ-결합능이 상실된 개선된 종양세포-특이 세포살상능을 나타내는 재조합 아데노바이러스
AU2008209759B2 (en) 2007-01-30 2013-03-21 Transgene S.A. Papillomavirus E2 polypeptide used for vaccination
WO2010084100A1 (en) 2009-01-20 2010-07-29 Transgene Sa Soluble icam-1 as biomarker for prediction of therapeutic response
SG2014014021A (en) 2009-03-24 2014-07-30 Transgene Sa Biomarker for monitoring patients
KR20120027146A (ko) 2009-04-17 2012-03-21 트랜스진 에스.에이. 환자를 모니터링하기 위한 바이오마커
ES2385251B1 (es) 2009-05-06 2013-05-06 Fundació Privada Institut D'investigació Biomèdica De Bellvitge Adenovirus oncolíticos para el tratamiento del cáncer.
MX337287B (es) 2009-07-10 2016-02-22 Transgene Sa Biomarcador para seleccionar pacientes y metodos relacionados.
US9657076B2 (en) 2012-10-23 2017-05-23 Emory University GM-CSF and IL-4 conjugates, compositions, and methods related thereto
CA3115891A1 (en) 2013-03-14 2014-09-25 Salk Institute For Biological Studies Oncolytic adenovirus compositions
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
KR20180112024A (ko) 2016-02-23 2018-10-11 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 바이러스 동역학에 미치는 영향 최소화를 위한 치료용 아데노바이러스의 외인성 유전자 발현
WO2018111767A1 (en) 2016-12-12 2018-06-21 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5801029A (en) * 1993-02-16 1998-09-01 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
CA2152941C (en) * 1993-02-16 2003-04-22 Francis Mccormick Cytopathic viruses for therapy and prophylaxis of neoplasia
WO1999031261A1 (en) * 1997-12-12 1999-06-24 Onyx Pharmaceuticals, Inc. SELECTIVE KILLING AND DIAGNOSIS OF p53+ NEOPLASTIC CELLS
US7078030B2 (en) * 1999-11-15 2006-07-18 Onyx Pharmaceuticals, Inc Oncolytic adenovirus
DK1230378T3 (da) * 1999-11-15 2007-10-08 Onyx Pharma Inc Et onkolytisk adenovirus

Also Published As

Publication number Publication date
US20020037274A1 (en) 2002-03-28
JP2004517798A (ja) 2004-06-17
CN1333689A (zh) 2002-01-30
EP1121137A1 (en) 2001-08-08
ES2245831T3 (es) 2006-01-16
AU6518799A (en) 2000-05-15
AU775611B2 (en) 2004-08-05
ATE299708T1 (de) 2005-08-15
DE69926251T2 (de) 2006-05-24
EP1121137B1 (en) 2005-07-20
WO2000024408A1 (en) 2000-05-04
CA2348634A1 (en) 2000-05-04
DE69926251D1 (de) 2005-08-25

Similar Documents

Publication Publication Date Title
DK1121137T3 (da) Fremgangsmåde til udryddelse af tumorer og tumorassocierede endotelceller under anvendelse af adenovirus af adenovirus-mutanter
HUP0101343A2 (hu) Antitest-citokin fúziós protein által közvetített immunválasz fokozása prosztaglandin-inhibitor együttes adagolásával
ZA200005475B (en) Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with anglogenesis inhibitor.
NO985574L (no) FremgangsmÕter og preparater anvendelige for inhibering av angiogenese
WO2002098897A3 (en) Modified antibodies to prostate-specific membrane antigen and uses thereof
WO2004098535A3 (en) Modified antibodies to prostate-specific membrane antigen and uses thereof
NO326660B1 (no) Imidazolyl-cykliske acetal forbindelser, farmasøytiske sammensetninger inneholdende disse forbindelser og anvendelse av forbindelsene
DE60017141D1 (de) Replikationskompetente anti-tumor vektoren
DK2269656T3 (da) Udvalgte antistoffer, som binder til aminophospholipider og deres anvendelse i behandling, så som cancer
AU7054798A (en) Modified adenoviral fiber and target adenoviruses
NO990086L (no) Avkortete, l°selige tumornekrosefaktorreseptorer av type I og type II
EP1767642A4 (en) CONSTRUCTION OF A RECOMBINANT OF ONCOLYTIC ADENOVIRUS SPECIFICALLY EXPRESSING A GM-CSF IMMUNOMODULATING FACTOR IN TUMOR CELLS AND USES THEREOF
WO2004094614A3 (en) Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
DE69940980D1 (de) Rana pipiens proteine und deren verwendung in der behandlung von tumoren
DK1185279T3 (da) Midler til behandling af maligne sygdomme ved anvendelse af proteinet YB-1
AU2002350623A1 (en) Targeted thrombosis by tissue factor polypeptides
WO2004035616A3 (de) Adenovirus mit umgekehrter reihenfolge der expression von genen und verwendung davon
AU2001233912A1 (en) Diagnosis of breast cancer using bcmp-81 as marker
WO2001072341A3 (en) Methods of treating neoplasia with combinations of target cell-specific adenovirus, chemotherapy and radiation
NO20021441L (no) Antistoff-fargestoffkonjugater mot angiogenesemålstrukturer for intraoperativ presentasjon av tumorperiferier
NO20021634D0 (no) Fremstilling av rekombinante adenoviruser og adenovirusbanker
Doloff et al. Adenoviral delivery of pan-caspase inhibitor p35 enhances bystander killing by P450 gene-directed enzyme prodrug therapy using cyclophosphamide+
DK1196188T3 (da) VGF-selektive monoklonale antistoffer og deres anvendelse til behandling af VGF-relaterede lidelser
MXPA02010974A (es) Metodos para inhibir la proliferacion e inducir apoptosis en celulas carcerosas.
DK1121439T3 (da) Fremgangsmåder og præparater til inhibering af neoplastisk cellevækst